Greenwich LifeSciences, Inc. (GLSI)
Develops cancer vaccines to prevent breast cancer recurrence in HER2-positive patients.
$13.28-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+19.7%
The outlook
GLSI is trading near its 52-week lows and below its key moving averages, signaling weakness in recent momentum. However, analyst coverage—though thin at just two analysts—rates the stock a Strong Buy with an average price target roughly 3.3x the current price. The overall picture shows a disconnect between bearish technicals and bullish analyst sentiment.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range21% of the way from its 52-week low to high
Price targetAvg target +329% vs current price
Analyst price target
~12-month · 2 analysts$57.00average target+329.2% vs now
Now $13.28
Low $45.00High $69.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$194.9M
52-wk high
$34.10
52-wk low
$7.78
50-day avg
$22.02
200-day avg
$20.18
Trailing P/E
—